Serum Surfactant Protein D (SP-D) is a Prognostic Marker of Poor Outcome in Patients with A/H1N1 Virus Infection

Delgado, Carlos Enrique Yepes; Krötzsch, Edgar; Jiménez-Álvarez, Luis Armando; Ramírez-Martínez, Gustavo; Márquez-García, José Eduardo; Cruz‐Lagunas, Alfredo; Morán, Juan; Hernández, Carmen; Sierra-Vargas, Patricia; Ávila‐Moreno, Federico; Becerril, Carina; Montaño, Martha; Banales-Mendez, José Luis; Zúñiga, Joaquı́n; Buendía-Roldán, Ivette

doi:10.1007/s00408-014-9669-3

Cited by 24 publications

(35 citation statements)

References 32 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SP-D as a marker for severity of pneumonia also has been studied before. [ 29 – 31 ] In accordance with the study of Leth-Larsen et al, we found SP-D levels to be significantly lower on day 0 in CAP patients compared to levels of healthy controls. [ 29 ] In contrast, two other studies showed high SP-D levels in respectively critically ill patients with acute respiratory distress syndrome (ARDS) suffering from A/H1N1 infection and CAP patients.…”

Section: Discussionsupporting

confidence: 90%

“…[ 29 ] In contrast, two other studies showed high SP-D levels in respectively critically ill patients with acute respiratory distress syndrome (ARDS) suffering from A/H1N1 infection and CAP patients. [ 31 , 32 ] This difference in findings could be caused by the moment of sampling and/or that the study of Delgado et al was performed in patients with ARDS, while our study excluded patient who were directly admitted to the intensive care unit (ICU). Lower SP-D levels found on day 0 might be due to less SP-D production by pneumocytes as a result of pulmonary infiltrates.…”

Section: Discussionmentioning

confidence: 94%

See 1 more Smart Citation

Course of SP-D, YKL-40, CCL18 and CA 15-3 in adult patients hospitalised with community-acquired pneumonia and their association with disease severity and aetiology: A post-hoc analysis

et al. 2018

View full text Add to dashboard Cite

Background and aimSP-D, YKL-40, CCL18 and CA 15–3 are pulmonary markers that have been extensively investigated in different chronic pulmonary diseases. However, in acute pulmonary diseases, such as community-acquired pneumonia (CAP), little is known about the course of these markers and their relationship with the aetiological agent. The aim of this study was to investigate the course of these four markers in CAP and to study influence of disease severity, aetiology and antibiotic use prior to admission on their course.MethodsWe included 291 adult patients hospitalised with CAP and 20 healthy controls. Measurements were performed in serum of day 0, 2, and 4, and at least 30 days after admission.ResultsOur most important results were: 1) At all time-points, including 30 days after admission, YKL-40 and CCL18 levels were higher in CAP patients compared to healthy controls; and 2) Patients with CAP caused by an intracellular, atypical bacterium had lower YKL-40 and especially CCL18 levels on and during admission in comparison with other or unknown CAP aetiology.ConclusionsOur findings suggest that these pulmonary markers could be useful to assess CAP severity and, especially YKL-40 and CCL18 by helping predict CAP caused by atypical pathogens.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 94%

Course of SP-D, YKL-40, CCL18 and CA 15-3 in adult patients hospitalised with community-acquired pneumonia and their association with disease severity and aetiology: A post-hoc analysis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Importantly, circulating surfactant protein levels may have clinical usefulness. One study demonstrated that surfactant protein levels can be used as an indicator of lung injury and poor outcomes in H1N1 viral infections (47), and another showed that SP-A and SP-D levels are elevated in those with pulmonary fibrosis compared with healthy volunteers (48).…”

Section: Pulmonary Disorders Related To Surfactant Dysfunction or Defmentioning

confidence: 99%

The Role of Surfactant in Lung Disease and Host Defense against Pulmonary Infections

Han¹,

2015

View full text Add to dashboard Cite

Pulmonary surfactant is essential for life as it lines the alveoli to lower surface tension, thereby preventing atelectasis during breathing. Surfactant is enriched with a relatively unique phospholipid, termed dipalmitoylphosphatidylcholine, and four surfactant-associated proteins, SP-A, SP-B, SP-C, and SP-D. The hydrophobic proteins, SP-B and SP-C, together with dipalmitoylphosphatidylcholine, confer surface tension-lowering properties to the material. The more hydrophilic surfactant components, SP-A and SP-D, participate in pulmonary host defense and modify immune responses. Specifically, SP-A and SP-D bind and partake in the clearance of a variety of bacterial, fungal, and viral pathogens and can dampen antigen-induced immune function of effector cells. Emerging data also show immunosuppressive actions of some surfactant-associated lipids, such as phosphatidylglycerol. Conversely, microbial pathogens in preclinical models impair surfactant synthesis and secretion, and microbial proteinases degrade surfactant-associated proteins. Deficiencies of surfactant components are classically observed in the neonatal respiratory distress syndrome, where surfactant replacement therapies have been the mainstay of treatment. However, functional or compositional deficiencies of surfactant are also observed in a variety of acute and chronic lung disorders. Increased surfactant is seen in pulmonary alveolar proteinosis, a disorder characterized by a functional deficiency of the granulocyte-macrophage colony-stimulating factor receptor or development of granulocyte-macrophage colony-stimulating factor antibodies. Genetic polymorphisms of some surfactant proteins such as SP-C are linked to interstitial pulmonary fibrosis. Here, we briefly review the composition, antimicrobial properties, and relevance of pulmonary surfactant to lung disorders and present its therapeutic implications.

show abstract

“…We demonstrated that serum SP-D concentrations are significantly reduced by chemotherapy in patients with pediatric ALL reaching a nadir on days 15-22 coinciding with a nadir of the white blood cell have been related to several different pulmonary pathologies and respiratory outcomes. [30][31][32][33][34] Previous studies indicated an association between circulating SP-D levels and mortality in elderly women 35 and A/H1N1-infected patients, 36 prognosis in patients with chronic kidney disease, 37 and cardiovascular morbidity and mortality. 38 In rheumatoid arthritis, SP-D levels are below normal in newly diagnosed and untreated patients, and are inversely correlated with systemic inflammation suggesting that low systemic SP-D levels may be involved in the initiation or maintenance of the inflammatory process.…”

Section: Discussionmentioning

confidence: 99%

Chemotherapeutic treatment reduces circulating levels of surfactant protein‐D in children with acute lymphoblastic leukemia

Rathe

Sørensen

Wehner

et al. 2016

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

Serum Surfactant Protein D (SP-D) is a Prognostic Marker of Poor Outcome in Patients with A/H1N1 Virus Infection

Abstract: Our results revealed that higher circulating levels of SP-D are associated with higher mortality risk in critically ill A/H1N1 patients. SP-D might be a predictive factor of poor outcomes in viral pneumonia.

Cited by 24 publications

References 32 publications

Course of SP-D, YKL-40, CCL18 and CA 15-3 in adult patients hospitalised with community-acquired pneumonia and their association with disease severity and aetiology: A post-hoc analysis

Course of SP-D, YKL-40, CCL18 and CA 15-3 in adult patients hospitalised with community-acquired pneumonia and their association with disease severity and aetiology: A post-hoc analysis

The Role of Surfactant in Lung Disease and Host Defense against Pulmonary Infections

Chemotherapeutic treatment reduces circulating levels of surfactant protein‐D in children with acute lymphoblastic leukemia

Contact Info

Product

Resources

About